Clinical Trial Update: Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of a dual PI3K Delta/Gamma inhibitor in B-cell and T-cell lymphomas has completed, assessing safety and preliminary efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• Dual PI3K Delta/Gamma Inhibitor

Snippet

Sponsor: Rhizen Pharmaceuticals SA | Conditions: Lymphoma, B-Cell, T-Cell Lymphoma | Phase 1 | Status: COMPLETED